Lung cancer (Amsterdam, Netherlands)HumansCarcinomaNon-Small-Cell LungMaleLung Neoplasms
Durvalumab in locally advanced unresectable non-small cell lung cancer - Benchmarking real-world outcomes in England against published trial data.
Laura Webster, Sarah Lawton, Emma Kipps, Katherine Thackray, Nadza Tokaca
Published: 202510.1016/j.lungcan.2025.108752
Abstract
BACKGROUND: Durvalumab after chemoradiotherapy (CRT) is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer based on the PACIFIC trial data. The National Institute for Health and Care Excellence recommended reimbu…
Preview only. Read the full abstract at the source